Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Aaron Ebbs"'
Publikováno v:
Genes & Cancer
Activating mutations in KRAS are prevalent in cancer, but therapies targeted to oncogenic RAS have been ineffective to date. These results argue that targeting downstream effectors of RAS will be an alternative route for blocking RAS-driven oncogenic
Autor:
Fan Pan, Ogert Fisniku, M S. Jang, and Hongsi Jiang, Aaron Ebbs, Hallgrimur Benediktsson, Leendert C. Paul, Carmen Wynn, Laurie Erickson, Masakazu Kobayashi, Gladys Crews
Publikováno v:
Transplantation. 75:1110-1114
Background. FK778 is a new derivative of the active leflunomide metabolite A77 1726. It effectively prevented acute allograft rejection in several experimental transplant models, and it is currently in phase II trials in human transplant recipients.
Publikováno v:
Transplantation. 73:1808-1817
Background Accumulated evidence from clinical transplantation has suggested that tacrolimus-based treatment can reverse ongoing allograft rejection in patients treated with cyclosporine (CsA)-based immunosuppression, even when a high dose of antireje
Publikováno v:
Cancer Research. 77:2877-2877
The heterogeneous nature of prostate cancer tumors is thought to play an important role in the decreased effectiveness of existing therapies. Tumor initiating cells (TICs) are capable of self-renewal and comprise a subset of the tumor mass. These cel
Autor:
Han C. Dan, Albert S. Baldwin, Manolis Pasparakis, Terry Van Dyke, Daniela S. Basseres, Aaron Ebbs
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Universidade de São Paulo (USP)
instacron:USP
The serine/threonine protein kinase Akt promotes cell survival, growth, and proliferation through phosphorylation of different downstream substrates. A key effector of Akt is the mammalian target of rapamycin (mTOR). Akt is known to stimulate mTORC1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b580b6b172261ab8d4d08b4de6f0f543
Publikováno v:
Cancer research. 70(9)
K-Ras–induced lung cancer is a very common disease, for which there are currently no effective therapies. Because therapy directly targeting the activity of oncogenic Ras has been unsuccessful, a different approach for novel therapy design is to id
Publikováno v:
Transplantation. 76(3)
BACKGROUND Gene expression profiling has the potential to produce new insights into complex biologic systems. To test the value of complement DNA arrays in identifying pathways involved in organ transplant rejection, we examined the gene expression p
Publikováno v:
Transplantation. 73(11)
Accumulated evidence from clinical transplantation has suggested that tacrolimus-based treatment can reverse ongoing allograft rejection in patients treated with cyclosporine (CsA)-based immunosuppression, even when a high dose of antirejection rescu
Publikováno v:
Cancer Research. 72:903-903
Lung cancer is the leading cause of cancer deaths in the world. In lung cancer, K-Ras oncogenic mutations are widespread, and compounds used to target the biological activity of the Ras proteins failed in clinical trials. Therefore, it is imperative